For adults seeking evidence-based approaches to cardiovascular protection, understanding exactly how botanical compounds act at the cellular level matters more than knowing that they "work." A detailed mechanistic review of Ginkgo biloba published in Acta Pharmacologica Sinica consolidates what is now understood about this ancient plant's pharmacology and, crucially, explains why its effects are plausible rather than merely anecdotal.
The review identifies the principal bioactive constituents — flavonoid glycosides such as quercetin and kaempferol derivatives, alongside terpenoids including ginkgolides A, B, and C and bilobalide — as the primary drivers of cardiovascular benefit. These compounds appear to act across multiple complementary pathways: inhibiting platelet-activating factor (PAF) receptor signaling to reduce thrombotic risk, modulating nitric oxide bioavailability to support endothelial function, attenuating oxidative stress through free radical scavenging, and suppressing pro-inflammatory cytokine cascades implicated in atherosclerotic plaque development. The review also examines ginkgo's apparent capacity to regulate lipid metabolism and reduce smooth muscle cell proliferation, two processes central to arterial narrowing.
Placing this review in broader context, Ginkgo biloba occupies an unusual position in cardiovascular research — it has generated decades of clinical interest yet remains outside mainstream cardiology guidelines. Large trials such as the GEM (Ginkgo Evaluation of Memory) study found no significant cardiovascular benefit at the population level, which complicates enthusiasm generated by mechanistic work. This tension — compelling cellular pharmacology paired with inconsistent clinical outcomes — is precisely what makes review articles like this valuable, and precisely where caution is warranted. Standardization of extract formulation (most studied preparations use EGb 761 at 240 mg/day), bioavailability differences between individuals, and the gap between isolated-pathway inhibition and whole-organism outcomes remain unresolved. This review reads as confirmatory and consolidating rather than paradigm-shifting, reinforcing mechanistic plausibility without resolving clinical translation questions.